HISTOGENICS CORPORATION (NASDAQ:HSGX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
At the 2017 annual meeting of stockholders of Histogenics
Corporation (the Company) held on June13, 2017 (the Annual
Meeting), the following proposals were submitted to the
stockholders of the Company:
| Proposal1: |
The election of three directors to serve as ClassIII directors for a term of three years until the 2020 annual meeting of stockholders. |
|
| Proposal2: |
The ratification of the selection of Grant Thornton LLP as the Companys independent registered public accounting firm for the fiscal year ending December31, 2017. |
For more information about the foregoing proposals, see the
Companys definitive proxy statement on Schedule 14A filed with
the Securities and Exchange Commission on April27, 2017 (the
Proxy Statement). Of the 22,168,090 shares of the Companys common
stock entitled to vote at the Annual Meeting, 19,131,296 shares,
or approximately 86.3%, were represented at the meeting in person
or by proxy, constituting a quorum. The number of votes cast for,
against or withheld, as well as abstentions and broker non-votes,
if applicable, in respect of each such matter is set forth below.
Proposal 1: Election of Directors.
The Companys stockholders elected the following two directors to
serve as ClassIII directors until the 2020 annual meeting of
stockholders. The votes regarding the election of directors were
as follows:
|
Director |
Votes For | VotesWithheld | BrokerNon-Votes | |||||||||
|
David Gill |
14,995,390 | 284,943 | 3,850,963 | |||||||||
|
John H. Johnson |
14,993,936 | 286,397 | 3,850,963 | |||||||||
|
Garheng Kong, M.D., Ph.D. |
14,993,936 | 286,397 | 3,850,963 |
Proposal 2: Ratification of Grant Thornton LLP.
The Companys stockholders ratified the selection of Grant
Thornton LLP as the Companys independent registered public
accounting firm for the fiscal year ending December31, 2016. The
votes regarding this proposal were as follows:
|
Votes For |
VotesAgainst |
VotesAbstaining |
||
|
19,112,883 |
15,269 | 3,144 |
About HISTOGENICS CORPORATION (NASDAQ:HSGX)
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.